1. Field of the Invention
The present invention is generally related to a probe for characterizing properties of plaque in a chronic total occlusion.
2. Background of the Invention
Stenotic lesions may comprise a hard, calcified substance and/or a softer thrombus material, each of which forms on the lumen walls of a blood vessel and restricts blood flow there through. Intra-luminal treatments such as balloon angioplasty (PTA, PTCA, etc.), stent deployment, atherectomy, and thrombectomy are well known and have proven effective in the treatment of such stenotic lesions. These treatments often involve the insertion of a therapy catheter into a patient's vasculature, which may be tortuous and may have numerous stenoses of varying degrees throughout its length. In order to place the distal end of a catheter at the treatment site, a guidewire is typically introduced and tracked from an incision, through the vasculature, and across the lesion. Then, a catheter (e.g. a balloon catheter), perhaps containing a stent at its distal end, can be tracked over the guidewire to the treatment site. Ordinarily, the distal end of the guidewire is quite flexible so that it can be rotatably steered and pushed through the bifurcations and turns of the typically irregular passageway without damaging the vessel walls.
In some instances, the extent of occlusion of the lumen is so severe that the lumen is completely or nearly completely obstructed, which may be described as a total occlusion. If this occlusion persists for a long period of time, the lesion is referred to as a chronic total occlusion or CTO. Furthermore, in the case of diseased blood vessels, the lining of the vessels may be characterized by the prevalence of atheromatous plaque, which may form total occlusions. The extensive plaque formation of a chronic total occlusion typically has a fibrous cap surrounding softer plaque material. This fibrous cap may present a surface that is difficult to penetrate with a conventional guidewire, and the typically flexible distal tip of the guidewire may be unable to cross the lesion.
Thus, for treatment of total occlusions, stiffer guidewires have been employed to recanalize through the total occlusion. However, due to the fibrous cap of the total occlusion, a stiffer guidewire still may not be able to cross the occlusion. When using a stiffer guidewire, great care must be taken to avoid perforation of the vessel wall.
Further, in a CTO, there may be a distortion of the regular vascular architecture such that there may be multiple small non-functional channels throughout the occlusion rather than one central lumen for recanalization. Thus, the conventional approach of looking for the single channel in the center of the occlusion may account for many of the failures. These spontaneously recanalized channels may be responsible for failures due to their dead-end pathways and misdirecting of the guidewires. Once a “false” tract is created by a guidewire, subsequent attempts with different guidewires may continue to follow the same incorrect path, and it is very difficult to steer subsequent guidewires away from the false tract.
Another equally important failure mode, even after a guidewire successfully crosses a chronic total occlusion, is the inability to advance a balloon or other angioplasty equipment over the guidewire due to the fibrocalcific composition of the chronic total occlusion, mainly both at the “entry” point and at the “exit” segment of the chronic total occlusion. Even with balloon inflations throughout the occlusion, many times there is no antegrade flow of contrast injected, possibly due to the recoil or insufficient channel creation throughout the occlusion.
Atherosclerotic plaques vary considerably in their composition from site to site, but certain features are common to all of them. They contain many cells; mostly these are derived from cells of the wall that have divided wildly and have grown into the surface layer of the blood vessel, creating a mass lesion. Plaques also contain cholesterol and cholesterol esters, commonly referred to as fat. This lies freely in the space between the cells and in the cells themselves. A large amount of collagen is present in the plaques, particularly advanced plaques of the type which cause clinical problems. Additionally, human plaques contain calcium to varying degrees, hemorrhagic material including clot and grumous material composed of dead cells, fat and other debris. Relatively large amounts of water are also present, as is typical of all tissue.
Successful recanalization of chronic total occlusions remains an area where improvements are needed. Approximately 30% of all coronary angiograms in patients with coronary artery disease will show a CTO and its presence often excludes patients from treatment by percutaneous coronary intervention. Acute success rates vary according to the duration of occlusion, the morphology of the lesion and the coronary anatomy, the experience of the operator, the degree of persistence employed, and the type of equipment used. Recanalization rates range between 45-80%, with the highest success in short, recently occluded (<1 month), non-calcified lesions.
It is desirable to be able to characterize the plaque in the CTO before attempting to cross the CTO with a guidewire to minimize potential trauma to the area of the lumen at or near the CTO. By being able to characterize the plaque, softer regions may be identified, which may increase the chance of success of crossing the CTO with a guidewire without damaging surrounding tissue.
The present invention describes an apparatus and method to characterize at least one property of a CTO and to visualize and track soft spots/channels through a CTO by characterizing at least one property of the CTO. The apparatus and method use ultrasound for invasive real time characterization of plaque in chronic total occluded coronary arteries.
According to an aspect of the present invention, there is provided a probe for detecting at least one property of a chronic total occlusion in a lumen. The probe includes an elongated member having a distal end configured to be inserted into the lumen, and an ultrasound transducer mounted at the distal end of the elongated member. The ultrasound transducer is configured to emit an ultrasonic signal and to receive a reflected signal from the chronic total occlusion. The probe also includes a processor configured to receive the reflected signal from the ultrasound transducer and convert the reflected signal to at least one property of the chronic total occlusion.
According to an aspect of the invention, there is provided a method for detecting at least one property of a chronic total occlusion in a vessel. The method includes steering an elongated member having an ultrasound transducer at a distal end thereof to a location in the vessel proximal to the chronic total occlusion, emitting an ultrasonic signal towards a portion of the chronic total occlusion, receiving a signal reflected from the portion of the chronic total occlusion, and correlating the received signal to at least one property of the chronic total occlusion.
According to an aspect of the invention, there is provided a method for traversing a chronic total occlusion. The method includes a) steering an elongated member having an ultrasound transducer at a distal end thereof to a location in the vessel proximal to the chronic total occlusion; b) emitting an ultrasonic signal from the ultrasound transducer towards a portion of the chronic total occlusion; c) receiving a signal reflected from the portion of the chronic total occlusion; d) correlating the received signal to a hardness of the chronic total occlusion; e) repositioning the elongated member to another location in the vessel; f) determining a soft spot in the chronic total occlusion based on repeating a)-e); g) penetrating a guidewire into the soft spot of the chronic total occlusion; and h) detecting penetration of the guidewire with bioelectrical impedance.
Embodiments of the invention will now be described, by way of example only, with reference to the accompanying schematic drawings in which corresponding reference symbols indicate corresponding parts, and in which:
The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and use of the invention. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
The probe 20 also includes a processor 40 that is connected to the proximal end 26 of the elongated member 22 and a user interface 42 that is connected to the processor 40. The processor 40 is configured to provide a signal to the ultrasound transducer 30 so that the transducer 30 will emit the ultrasonic signal 32. The processor 40 is also configured to receive the reflected signal 34 from the transducer 30 and convert the reflected signal to at least one property of the CTO 14, as discussed in further detail below.
The user interface 42 may include one or more input devices 44 that allow the operator of the probe 20 to turn the probe 20 on and off, adjust settings, trigger the processor 30 to provide the signal to the transducer 30, etc. The input devices 44 may include buttons, switches, knobs, or any other suitable devices that allow the operator to change a condition of the probe 20. The user interface 42 also includes one or more output devices 46 that are configured to provide the operator with information about the probe 20 and the CTO 14. For example, the output devices 46 may include a video monitor that provides graphics representing at least one property of the CTO 14 being measured by the probe 20, and lights representing a condition of the probe 20, e.g., whether the probe is on or off, etc.
In operation, the probe 20 provides the clinician with continuous information on at least one property, such as the hardness or composition, of the CTO 14 that is just distal to the distal end 54 of the guidewire 50.
Analysis of the reflected signals 60, 62 may also provide information on the composition of the plaque. Identification of an area of the CTO 14 that includes soft plaque 16, i.e., a “soft spot”, provides information to the clinician on the location to enter the CTO 14. Once the transducer 52 has entered the CTO, further information on the composition of the CTO 14 may be provided by continuing CTO 14 characterization, i.e., measuring the reflected signal 34 received by the transducer 52 over time. For example, if the probe 20 indicates a transition from soft plaque 16 to hard plaque 18, the transducer 52 may be at a dead-end or at a curve of the lumen 12 and CTO 14, which would indicate that the guidewire 50 would need to be steered in a different direction to continue to traverse the CTO.
In an embodiment, the transducer 52 may be used to create a hardness “map” of plaque formation, such as the CTO 14, within the lumen 12. An example of a hardness map 70 is shown in
The position of the distal end 54 of the guidewire 50 within the lumen 12 may be measured by at least two additional ultrasound transducers 72, shown in
After the guidewire 50 enters the CTO 14 through a soft spot, i.e., a relatively soft area of plaque as detected by the probe 20, contact with the wall 11 of the vessel may be detected by continuously recording an electrocardiogram (“ECG”). As illustrated in
The impedance may be measured between the distal end 54 of the guidewire 50, which is insulated, and at least one conductive element 94. An example of a system that uses bioelectrical impedance to guide a flexible elongated transluminal device through an occlusion is described in United States Patent Application Publication No. 2007/0255270, which is incorporated by reference in its entirety.
As illustrated in
The impedance may be measured between the distal end 54 of the guidewire 50 and the conductive element 94 on the balloon 92, once the balloon 92 has been inflated against the inner wall 11 of the lumen 12 of the vessel 10. An alternating current I may be used to prevent hydrolysis and stimulation of the heart, and may be provided by a circuit 96 shown in
In an embodiment, the at least one conductive element 94 may be a bipolar pair of electrodes (not shown) that may be provided at the distal end 54 of the guidewire 50. The electrodes may be ring electrodes and spaced apart at a distance so that the inner ring electrode is located at the distal end 54 of the guidewire 50, and the outer ring electrode is configured to contact the wall 11 of the vessel 10. In such an embodiment, the balloon 92 of
The piezoelectric material may include lead zirconate titanate, but could also be any other piezoelectric material, including capacitive micromachined ultrasound transducers. In an embodiment, as many as four micromachined ultrasound transducers may be provided in the circular array 108 to allow the ultrasonic signals to be steered. In this way, the CTO 14 can be characterized by multiple elements that create a circumferential view of the CTO 14 so that the locations of the soft plaque 16 and the hard plaque 18 may be identified and output to the user interface 50.
In an embodiment, the guidewire 50 discussed above may be used with the guide catheter 100. Such an arrangement would allow the position of the guidewire 50 that is equipped with the single element ultrasound transducer 52, or the ultrasound transducer 80 having the annular array of transducers 82, to be monitored by the ultrasound transducer elements 104 on the guide catheter 100. By combining this with the CTO hardness map 70 obtained by ultrasound characterization, information may be provided to the clinician on where the distal end of the guidewire is currently located and where the distal end of the guidewire should be. In other words, the clinician may be given guidance on how to reposition the guidewire towards a CTO “soft spot”. Imaging the lumen 12 of the vessel 10 may provide additional information on the localization of the catheter.
While at least one exemplary embodiment has been presented in the foregoing detailed description of the invention, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient roadmap for implementing an exemplary embodiment of the invention, it being understood that various changes may be made in the function and arrangement of elements described in an exemplary embodiment without departing from the scope of the invention as set forth in the appended claims.